GERCOR - Multidisciplinary Oncology Cooperative Group
GERCOR - Multidisciplinary Oncology Cooperative Group
Explore linked clinical trials.25 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| POP-UP: a Single-arm, Two-cohort Study: an 8-week Trimodal Pre-habilitation Program for Patients With Pancreatic Ductal Adenocarcinoma and Oesogastric | Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, esophageal cancer, esophageal disorder, neoplasm, pancreatic ductal adenocarcinoma | Recruiting | Not applicable | 2026-09-17 | NCT06275737 | |
| Acupuncture for Oxaliplatin-induced Peripheral Neuropathy in Gastro-intestinal Cancer Patients | Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Neoplasms by Site, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, esophageal cancer, esophageal disorder, gastric cancer, gastric neoplasm, intestinal disorder, liver cancer, liver disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm, rectal disorder, stomach disorder | Recruiting | Not applicable | 2026-09-11 | NCT05850130 | |
| DEWI: Watch-and-Wait With Dostarlimab in Localized dMMR/MSI-H Gastric/GEJ Adenocarcinoma Phase II Study | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Recruiting | Phase 2 | 2026-08-26 | NCT06059495 | |
| Study of Occupational Risk Factors for Biliary and Pancreatic Cancers | Biliary Tract Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, biliary tract cancer, biliary tract disorder, endocrine system disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Not yet recruiting | Not stated | 2026-06-25 | NCT07668024 | |
| Sotorasib Combined With First-line Chemotherapy for Advanced Pancreatic Adenocarcinoma | pancreatic adenocarcinoma | Recruiting | Phase 1 | 2026-04-30 | NCT06892054 | |
| Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Recruiting | Phase 2 | 2026-03-16 | NCT05528952 | |
| First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, gastric cancer, gastric neoplasm, neoplasm, stomach disorder | Recruiting | Phase 2 | 2025-09-22 | NCT06253611 | |
| LONsurf and G-CSF Use: Being On A Right Dose-intensity to Optimize Treatment Efficacy | Cytopenia, Digestive System Diseases, Digestive System Neoplasms, Hemic and Lymphatic Diseases, Neoplasms by Site, agranulocytosis, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, hematologic disorder, intestinal disorder, leukocyte disorder, leukopenia, neoplasm, neutropenia, rectal disorder | Active, not recruiting | Phase 2 | 2025-08-19 | NCT04166604 | |
| Maintenance With Olaparib or Selumetinib + Durvaluma for m-PDAC Guided by BRCAness and KRAS Status. | Metastatic Pancreatic Adenocarcinoma | Active, not recruiting | Phase 2 | 2025-07-25 | NCT04348045 | |
| OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDAC | Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, metastatic malignant neoplasm, neoplasm, pancreatic ductal adenocarcinoma | Active, not recruiting | Phase 2 | 2025-07-25 | NCT03806309 | |
| ctDNA in CRC Patients Undergoing Curative-intent Surgery for Liver Metastases | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Not stated | 2025-07-23 | NCT05787197 | |
| Prognostic and Predictive Markers of Response to Treatment in Patients With Bile Duct Cancer: ACABi PRONOBIL Study | Biliary Tract Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, biliary tract cancer, biliary tract disorder, neoplasm | Recruiting | Not stated | 2025-07-23 | NCT04935853 | |
| Efficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive Neuroendocrine Carcinomas | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, adenocarcinoma, carcinoma, digestive system disorder, digestive system neoplasm, epithelial neoplasm, neoplasm, neuroendocrine carcinoma, neuroendocrine neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 2 | 2025-07-23 | NCT04268121 | |
| Durvalumab + Tremelimumab ± Paclitaxel in Advanced BTC After Platinum Chemotherapy. | Advanced Biliary Tract Carcinoma | Active, not recruiting | Phase 2 | 2025-07-23 | NCT03704480 | |
| iRECIST Evaluation's Relevance for DCR in MMR/MSI Metastatic Colorectal Cancer Patients on Nivolumab and Ipilimumab | Digestive System Diseases, Digestive System Neoplasms, Genomic Instability, Microsatellite Instability, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, colonic disorder, colonic neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm | Active, not recruiting | Phase 2 | 2025-07-23 | NCT03350126 | |
| QoL in mCRC Elderly Patients Receiving First-line Therapy Based on Simplified Geriatric Parameters. | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Active, not recruiting | Phase 3 | 2025-07-18 | NCT03828227 | |
| BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients | Cytopenia, Digestive System Diseases, Digestive System Neoplasms, Hemic and Lymphatic Diseases, Neoplasms by Site, agranulocytosis, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, hematologic disorder, intestinal disorder, leukocyte disorder, leukopenia, neoplasm, neutropenia, rectal disorder | Not yet recruiting | Phase 2 | 2025-07-17 | NCT07071844 | |
| PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment | PDAC - Pancreatic Ductal Adenocarcinoma | Not yet recruiting | Phase 2 | 2025-07-01 | NCT07028424 | |
| Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Phase 2 | 2025-07-01 | NCT05310643 | |
| Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma. | Genomic Instability, Microsatellite Instability, Pathologic Processes, Pathological Conditions, Signs and Symptoms | Active, not recruiting | Phase 2 | 2025-06-15 | NCT04006262 | |
| Neoadjuvant Pembrolizumab With a Watch-and-wait Strategy for dMMR/MSI-H Localized Colon Cancer: PREMICES Study. | Digestive System Diseases, Digestive System Neoplasms, Genomic Instability, Microsatellite Instability, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, colonic disorder, colonic neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, malignant colon neoplasm, mismatch repair cancer syndrome 1, neoplasm | Not yet recruiting | Phase 2 | 2025-06-13 | NCT06646445 | |
| Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC. | Colorectal Cancer Metastatic; MSI-H Colorectal Cancer | Active, not recruiting | Phase 2 | 2025-06-13 | NCT04730544 | |
| Management of Symptomatic Advanced Pancreatic Adenocarcinoma | Management Supportive Care Program; Pancreas | Active, not recruiting | Not applicable | 2025-06-13 | NCT02979483 | |
| Prognostic and Predictive Markers of Treatment Response in Patients With PAC. | pancreatic adenocarcinoma | Recruiting | Not stated | 2025-03-25 | NCT05776342 | |
| Two Therapeutic Strategies in First-line in Patients With Epithelial Advanced Ovarian Cancer | Adnexal Diseases, Carcinoma, Ovarian Epithelial, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, carcinoma, endocrine system disorder, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder | Recruiting | Phase 2 | 2021-02-11 | NCT03025477 |